This letter to the editor builds on the findings of a recent article by Hernandez and colleagues on the impact of comorbid posttraumatic stress disorder on outcomes of treatment with repetitive transcranial magnetic stimulation in depressed veterans.
The objective of this study was to investigate the prevalence of depression, anxiety, and insomnia among hospital staff working in a tertiary care private hospital in India during the early period of the COVID-19 pandemic.
Novel approaches are needed to assist rural primary care physicians in caring for older patients living with depression and pain who are at an elevated suicide risk. Read this article to find out more about the PREDICTOR model.
The link between suicidality and interpersonal difficulties extends the traditional approach of comprehending suicide as mainly related to depression. This study of adult outpatients investigated the link between separation anxiety disorder and suicidality.
How prevalent is treatment-resistant depression (TRD), and what proportion of the burden of medication-treated major depressive disorder is accounted for by TRD? This study explores those questions using the most commonly accepted definition of TRD.
Patients with multiple sclerosis commonly have neuropsychiatric comorbidity. ECT may be used to treat severe and life-threatening forms of mental illness when other modalities have failed or when a rapid response is required. Read on to find out more.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”